Antibiotic Susceptibility and Treatment of Brucellosis
Jaffar A. Al-Tawfiq and Ziad A Memish
Affiliation: Ministry of Health, P.O. Box 54146, Riyadh 11514, KSA.
Keywords: Brucellosis therapy, antibiotics, antimicrobials, FOCAL DISEASES, BRUCELLA ENDOCARDITIS, valvular destruction, abscesses, ceftriaxone, trimethoprim-sulfamethoxazole, negative outcome
Brucellosis, a zoonotic infection caused by the genus Brucellae, is an ancient condition linked to the consumption
of milk and milk products. The disease has global importance due to its impact. Therapeutic options for brucellosis
rely mostly on uncontrolled, nonrandomized, non-blinded studies. The choice and duration of therapy are related to patient
characteristics and the presence of a focal disease. The usual therapy of acute brucellosis is a combination of doxycycline
plus rifampicin for 6 weeks. An aminoglycoside could be substituted for rifampin for the initial week of combination
therapy. Other alternatives include a combination of doxycycline plus trimethoprim-sulfamethoxazole, or a fluoroquinolone
plus rifampicin. The presence of spondylitis or endocarditis usually indicates that the required treatment will be of
a longer duration or a combination of therapy. The article has the discussion of some recent patents related to antibiotic
susceptibility and Brucellosis.
Rights & PermissionsPrintExport